
| RESEARCH ARTICLE

Clinical and Radiological Features of Familial Multiple Sclerosis in Comparison to Sporadic Multiple Sclerosis in Iraqi Patients

Ali Mohammed Khaleel¹ ✉ and Sarmad Abdul-Rasool Al-Mashetah²

^{1,2}*Baghdad Teaching Hospital, Faculty of Neurology, Baghdad, Iraq*

Corresponding Author: Ali Mohammed Khaleel, **E-mail:** daodaoy87@yahoo.com

| ABSTRACT

Multiple Sclerosis (MS) is a complex autoimmune disease affecting the central nervous system, characterized by diverse symptoms based on lesion locations. Familial MS (FMS) indicates a genetic predisposition, potentially leading to a more severe disease course than sporadic MS, which lacks familial clustering. This distinction is critical for diagnosing and treating MS, particularly in the Iraqi patient population. The study aims to evaluate and compare the clinical and radiological features of FMS and sporadic MS among patients at the Baghdad Teaching Hospital's MS outpatient clinic. In this observational retrospective cross-sectional study, conducted from July 1, 2023, to December 31, 2023, at the Baghdad M.S outpatient clinic within the Medical City complex in Baghdad, Iraq, 100 MS patients were enrolled, with an equal division between FMS (n=50) and sporadic MS (n=50) cases. Participants were selected based on a definitive MS diagnosis, with FMS patients having a first or second-degree relative with MS. Data were collected via a questionnaire focusing on demographics, clinical presentations, MRI findings, and EDSS scores. Analysis was performed using SPSS version 26, employing Pearson Chi-square tests and Fisher's Exact test, with significance set at $P \leq 0.05$. The demographic analysis revealed a predominant female representation (89%), with a significant age range between 20-30 years (48%). Time to diagnosis was notably longer for FMS cases, averaging 25.235 months, compared to 10.295 months for sporadic cases ($P=0.002$). Clinical presentations did not significantly differ between groups, but FMS cases exhibited greater disability severity, with higher EDSS scores indicating moderate to severe disability in 31% of FMS cases compared to only 19% in sporadic cases ($P=0.035$). MRI findings showed a higher prevalence of spinal cord and corpus callosum lesions in FMS ($P=0.001$ and $P=0.027$, respectively), with no significant differences in juxtacortical, cortical, or infratentorial lesions. This study illuminates that MS mainly affects females in their twenties and thirties, with familial MS cases taking longer to diagnose than sporadic ones. Familial cases exhibited more severe disabilities and more lesions in the spinal cord and corpus callosum. This indicates a complex interplay between genetics and MS, underscoring the importance of further research to enhance our understanding of the disease.

| KEYWORDS

Multiple Sclerosis, Familial MS, Sporadic MS, Radiological Features.

| ARTICLE INFORMATION

ACCEPTED: 01 February 2024

PUBLISHED: 04 March 2024

DOI: 10.32996/bjbs.2024.4.1.1

1. Introduction

Multiple sclerosis (MS) is an autoimmune disorder affecting the central nervous system, characterized by inflammation, demyelination, gliosis, and neuronal loss, leading to a variety of neurological symptoms determined by lesion locations. Familial MS (FMS) is distinguished by genetic predisposition and potentially more severe progression compared to sporadic MS, which lacks familial clustering. This differentiation is crucial for diagnosis and treatment, especially in Iraqi patients [Eva et al. 2023, Katsavos et al. 2019, AlJumah et al. 2020].

MS is categorized into several types based on disease progression: Relapsing-Remitting (RR), Primary Progressive (PP), Secondary Progressive (SP), Progressive-Relapsing (PR), Clinically Isolated Syndrome (CIS), Fulminant MS, and Benign MS. RRMS, the most common form, features acute relapses with potential disability accumulation, while PPMS and SPMS show gradual deterioration [Manjunatha et al 2022, Amezcua 2022, Younger 2022]

The cause of MS is multifactorial, involving immune, environmental, and genetic factors. Immune dysregulation, particularly involving CD4+ T cells, environmental factors such as vitamin D deficiency and infections, and genetic predispositions underscore the complex interplay in MS development [Fymat 2023, Dhaiban et al. 2021]

Globally, MS affects approximately 2.5 million people, with a higher prevalence in females and a typical onset between 20 and 40 years. Geographical and ethnic variations in MS prevalence and clinical severity suggest environmental and genetic influences. Familial cases exhibit increased risk and potentially distinct clinical presentations among different ethnic groups [Ponzio et al. 2022, Eskandarieh et al. 2018]

Pathophysiologically, MS is marked by focal inflammation leading to plaques and neurodegeneration across the CNS. B cells and antibody production also contribute to the disease's complex pathogenesis, highlighting the need for understanding these processes for targeted treatment approaches [Kamma et al. 2022, Sun et al. 2023]

Clinically, MS manifests with a wide range of symptoms, including visual disturbances motor, sensory, cognitive, and urinary issues, reflecting the multifocal nature of CNS lesions. The disease primarily follows a relapsing-remitting course, with variable progression to more severe forms. The Expanded Disability Status Scale (EDSS) is used to assess disability levels in both familial and sporadic MS, aiding in disease management and monitoring [Schmidt et al 2019]

MS diagnosis involves clinical, radiological, and laboratory assessments, including MRI and cerebrospinal fluid analysis, to identify characteristic lesions and immune markers. Routine blood tests are also crucial to exclude other potential causes of the symptoms [Ömerhoça et al. 2018, Zivadinov et al. 2018]

Management strategies focus on disease-modifying therapies (DMTs) for RRMS to reduce disease activity and prevent disability progression, with specific treatments for acute relapses and symptomatic care. The effectiveness of DMTs varies across different MS forms, emphasizing the importance of early initiation and patient compliance [Piehl et al. 2021]

The prognosis for MS varies widely, influenced by factors such as gender, disease course, and initial symptoms. Complications include impaired mobility, visual disturbances, and cognitive challenges, requiring comprehensive management strategies [Bsteh et al. 2016, Amini et al. 2021]

2. Patients and methods:

An observational retrospective cross-sectional analysis was conducted at the Baghdad M.S outpatient clinic within the Medical City complex in Baghdad, Iraq. Its primary aim was to evaluate the clinical and radiological characteristics distinguishing Familial Multiple Sclerosis (FMS) from sporadic MS cases. The research spanned from July 1, 2023, to December 31, 2023, and involved 100 participants—50 diagnosed with FMS and 50 with sporadic MS. Eligibility for the study was determined by a definitive MS diagnosis, having a first or second-degree relative with MS, and willingness to participate. Exclusions were made for non-definitive MS diagnoses, absence of familial MS history, incomplete data, or refusal to participate.

Data collection hinged on a comprehensive questionnaire developed post-review of scientific literature, encapsulating variables such as age at onset, familial closeness, clinical presentations, MRI findings at onset, progression rates to Secondary Progressive MS (SPMS), treatment adjustments, and Kurtzke's Expanded Disability Status Scale (EDSS) scores. A convenient sampling technique was employed due to time constraints.

For data analysis, responses were coded, serialized, and input into SPSS version 26 under the guidance of an academic supervisor. The analysis focused on simple statistical measures—frequency, percentage, mean, and standard deviation—and assessed differences using Pearson Chi-square tests and Fisher's Exact test as appropriate, with a significance threshold at $P \leq 0.05$.

Ethical considerations were meticulously observed, ensuring participant confidentiality and obtaining necessary clearances from both the Arabic Scientific Council for Neurology and the Iraqi Ministry of Health, emphasizing the study's commitment to ethical standards and data integrity for research purposes only.

3. Results:

This study, conducted at Baghdad Teaching Hospital's MS clinic, enrolled 100 MS patients, split evenly between familial MS (FMS) and sporadic MS cases. The demographic and diagnostic profile showed a predominant female composition (89%) and a mean

age of 29.35 years. The diagnosis time averaged 17.76 months, highlighting the patient demographics and initial disease assessment (Table 1).

Table 1 Demographic and Diagnostic Profile of MS Patients.

Variables		No.	%
Gender	Male	11	11.0
	Female	89	89.0
Age	Less than 20 years old	15	15.0
	20-30 years old	48	48.0
	31-40 years old	26	26.0
	more than 40 years old	11	11.0
	Mean \pm SD	29.35 \pm 9.109	
Time to Diagnosis (months)	Mean \pm SD	17.76 \pm 24.5	

Comparative analysis of demographic variables found no significant differences in gender and age distribution between FMS and sporadic MS cases, although FMS cases had a notably longer time to diagnosis, which was statistically significant ($p = 0.002$), suggesting potential delays in recognizing familial cases (Table 2).

Table 2 Analysis of Demographic Variables in Familial versus Sporadic Multiple Sclerosis Cases.

Variables		Familial		Sporadic		P value
		No	%	No	%	
Gender	Male	8	72.7	3	27.3	0.110
	Female	42	47.2	47	52.8	
Age	< 20 years	7	46.7	8	53.3	0.712
	20-30 years	22	45.8	26	54.2	
	31-40 years	14	53.8	12	46.2	
	> 40 years	7	63.6	4	36.4	
Age	Mean \pm SD	30.76 \pm 9.665		27.94 \pm 8.377		0.122
Time to DX	Mean \pm SD	25.235 \pm 30.2074		10.295 \pm 13.9306		0.002

Clinical variable analysis (Table 3) indicated no significant differences between FMS and sporadic MS in terms of motor, sensory, cerebellar, double vision, optic neuritis, and sphincter symptoms, suggesting similar clinical presentations for both groups.

Table 3 Analysis of Clinical Variables in Familial versus Sporadic Multiple Sclerosis Cases.

Variables		Familial		Sporadic		P value
		No	%	No	%	
Motor	No	23	50.0	23	50.0	-
	Yes	27	50.0	27	50.0	
Sensory	No	28	48.3	30	51.7	0.685
	Yes	22	52.4	20	47.6	
Cerebellar	No	36	48.7	39	51.3	0.488
	Yes	14	54.2	11	45.8	
Double vision	No	38	50.0	38	50.0	-
	Yes	12	50.0	12	50.0	
Optic neuritis	No	33	47.1	37	52.9	0.383
	Yes	17	56.7	13	43.3	
Sphincter	No	43	52.4	39	47.6	0.298
	Yes	7	38.9	11	61.1	

The comparative analysis of relapse frequency, MS types, and disability severity (Table 4) revealed no significant difference in relapse rates and MS types between the groups. However, a notable difference was observed in EDSS scores, with FMS cases showing a higher severity of disability ($p = 0.035$), indicating potentially more aggressive disease progression in familial cases.

Table 4 Comparative Analysis of Relapse Frequency, MS Types, and Disability Severity in Familial versus Sporadic MS Cases

Variables		Familial		Sporadic		P value
		No	%	No	%	
No of relapse in first year	0	18	42.9	24	57.1	0.534
	1	26	54.2	22	45.8	
	2	3	50.0	3	50.0	
	3	3	75.0	1	25.0	
Type of M. S	PPMS	1	33.3	2	66.7	0.558
	RRMS	49	50.5	48	49.5	
EDSS categories	0-2 (Mild)	19	38.8	30	61.2	0.035
	2-4 (Moderate)	19	54.3	16	45.7	
	> 4 (Severe)	12	75.0	4	25.0	
EDSS	Mean±SD	2.410± 1.6772		1.440± 1.3118		0.002

MRI lesion locations (Table 5) showed no significant difference in juxtacortical, cortical, and infratentorial lesions between FMS and sporadic MS. However, a significant association was found with spinal cord and corpus callosum lesions in FMS cases ($p = 0.001$ and $p = 0.027$, respectively), highlighting distinct radiological features that may differentiate familial from sporadic MS cases.

Table 5 The association of the MRI findings with the MS groups.

MRI findings		Familial		Sporadic		P value
		No	%	No	%	
juxtacortical	No	29	47.5	32	52.5	0.539
	Yes	21	53.8	18	46.2	
Cortical	No	29	48.3	31	51.7	0.683
	Yes	21	52.5	19	47.5	
Periventricular	No	18	64.3	10	35.7	0.075
	Yes	32	44.4	40	55.6	
Infratentorial	No	37	51.4	35	48.6	0.656
	Yes	13	46.4	15	53.6	
Spinal cord	No	30	40.5	44	59.5	0.001
	Yes	20	76.9	6	23.1	
CC	No	43	46.7	49	53.3	0.027
	Yes	7	87.5	1	12.5	

4. Discussion:

This study analyzed 100 MS patients at Baghdad Teaching Hospital, equally divided into familial MS (FMS) and sporadic MS groups, reflecting on gender prevalence, age distribution, and diagnostic timelines in alignment with Al-Hamadani et al. (2012) and supported by National MS Society findings on gender susceptibility [Al-hamadani et al. 2012, Langer-Gould et al. 2022]. The majority were females (89%), with the prevalent age of diagnosis in the late twenties, similar to Walton et al. (2020), highlighting the challenges in early MS detection [Walton et al. 2020]. Notably, FMS cases had a longer diagnosis duration compared to sporadic cases, suggesting complexities in recognizing familial patterns, a finding echoed by Moghadam et al. (2021).

The study found no significant difference in gender and age between FMS and sporadic MS, indicating these factors do not distinguish between the two types, aligning with Ehtesham et al. (2021). Clinical symptom analysis revealed no significant differences in motor, sensory, cerebellar, double vision, and optic neuritis symptoms between FMS and sporadic MS, suggesting these symptoms are not distinct to either group, supported by Bunul et al. (2023) and An-Najah journals [2021].

Disability severity, measured by EDSS scores, showed significant differences, with FMS cases exhibiting higher disability, suggesting a more aggressive disease progression, corroborated by Steenhof et al. (2019) and Faraji et al. (2022) in Iran, emphasizing the need for tailored management in familial MS. However, relapse frequency and MS type distribution did not significantly differ between familial and sporadic cases, suggesting these aspects do not influence the MS form, as indicated by Rojas et al. (2016).

MRI analysis revealed significant findings in spinal cord and corpus callosum lesions, markedly higher in FMS, suggesting potential genetic or familial components to disease pathology, a notion supported by Mokhtari et al. (2023) and Grudziecka Pyrek et al. (2022). However, no significant differences were found in juxtacortical, cortical, periventricular, and infratentorial lesions, indicating these are not distinctive markers between FMS and sporadic MS, akin to findings by Moghadam et al. (2021).

This study's limitations include its small sample size and geographic focus, reliance on retrospective data that may introduce bias, lack of detailed genetic analysis, and its cross-sectional design, which limits understanding of MS progression and the differentiation between familial and sporadic MS cases over time.

5. Conclusions:

Our research uncovered that MS predominantly affects females, particularly in their twenties and thirties, with familial MS cases showing a longer duration to diagnosis compared to sporadic ones. Interestingly, the type of MS—familial or sporadic—had no significant impact on clinical symptoms, including motor and sensory functions. However, familial MS was associated with greater disability severity and a higher prevalence of lesions in the spinal cord and corpus callosum, unlike sporadic MS, where such distinctions were not observed. These findings suggest a complex relationship between genetics and MS manifestations, highlighting the need for further studies to deepen our understanding of this condition.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.

References

- [1] AlJumah M, Otaibi HA, Al Towajri G, Hassan A, Kareem A and Kalakatawi M, et al. (2020). Familial aggregation of multiple sclerosis: Results from the national registry of the disease in Saudi Arabia. *Mult Scler J Exp Transl Clin*. 2020 Oct 12;6(4):2055217320960499.
- [2] Amezcua L. (2022). Progressive multiple sclerosis. *CONTINUUM: Lifelong Learning in Neurology*. 2022 Aug 1;28(4):1083-103.
- [3] Amini P, Almasi-Hashiani A, Sahraian MA, Najafi M and Eskandarieh S. (2021) Multiple sclerosis projection in Tehran, Iran using Bayesian structural time series. *BMC neurology*. 2021 Jun 24;21(1):235.
- [4] Al-hamadani HA, Marah HA and Al-Saffar F. (2012). Comparison of familial and sporadic multiple sclerosis in Iraqi patients. *Journal of the Faculty of Medicine Baghdad*. 2012 Apr 1;54(1):1-6.
- [5] Bunul SD. (2023). Comparing Clinical and Radiological Features in Familial and Sporadic Multiple Sclerosis. *Cureus*. 2023 Sep 1;15(9).
- [6] Bsteh G, Ehling R, Lutterotti A, Hegen H, Di Pauli F and Auer M, et al. (2016) Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study. *PLoS One*. 2016 Jul 8;11(7):e0158978.
- [7] Dhaiban S, Al-Ani M, Elemam NM, Al-Aawad MH, Al-Rawi Z and Maghazachi AA. (2021). Role of peripheral immune cells in multiple sclerosis and experimental autoimmune encephalomyelitis. *Sci*. 2021 Feb 1;3(1):12.
- [8] Ehtesham N, Rafie MZ and Mosallaei M. (2021) The global prevalence of familial multiple sclerosis: an updated systematic review and meta-analysis. *BMC neurology*. 2021 Dec;21:1-6.
- [9] Eva L, Pleş H, Covache-Busuioac RA, Glavan LA, Bratu BG, Bordeianu A, et al. (2023). A Comprehensive Review on Neuroimmunology: Insights from Multiple Sclerosis to Future Therapeutic Developments. *Biomedicines*. 2023 Sep 8;11(9):2489.
- [10] Eskandarieh S, Allahabadi NS, Sadeghi M and Sahraian MA. (2018) Increasing prevalence of familial recurrence of multiple sclerosis in Iran: a population based study of Tehran registry 1999-2015. *BMC Neurol*. 2018 Feb 7;18(1):15.
- [11] Fymat AL. (2023). Multiple sclerosis: I. Symptomatology and etiology. *Neurology and Psychology Research J*. 2023 May 20;4(1):1-46.
- [12] Faraji F, Mohaghegh P and Talaie A. (2022) Epidemiology of familial multiple sclerosis and its comparison to sporadic form in Markazi Province, Iran. *Multiple Sclerosis and Related Disorders*. 2022 Dec 1;68:104231.
- [13] Grudziecka P M and Selmaj K. (2022) Optical coherence tomography assessment of axonal and neuronal damage of the retina in patients with familial and sporadic multiple sclerosis. *Frontiers in Neurology*. 2022 Sep 16;13:953188.
- [14] Jbara A, Saidi I, Ishtayah M, Ghanim M, Al-Othman N and Rabayaa M. (2021) Familial versus sporadic multiple sclerosis in Palestine: a retrospective cross-sectional pilot study. *Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.)*. 2021 Dec 6;8(1): None-.
- [15] Kamma E, Lasisi W, Libner C, Ng HS and Plemel JR. (2022). Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics. *Journal of neuroinflammation*. 2022 Feb 10;19(1):45.
- [16] Katsavos S, Artemiadi A, Gontika M, Skarlis C, Markoglou N and Davaki P, et al. (2019) HLA-DRB1 differences in allelic distribution between familial and sporadic multiple sclerosis in a Hellenic cohort. *Postgraduate Medicine*. 2019 Oct 3;131(7):490-5.
- [17] Langer-Gould AM, Gonzales EG, Smith JB, Li BH and Nelson LM. (2022) Racial and ethnic disparities in multiple sclerosis prevalence. *Neurology*. 2022 May 3;98(18):e1818-27.
- [18] Moghadam NB, Ghaffari M, Rashed SS, Valaie N, Hesami O, Niloofar P and Ghazanfari Y. (2021). MRI but not demographic or clinical characteristics differ between familial and sporadic MS cases. *Multiple Sclerosis and Related Disorders*. 2021 Nov 1;56:103235.

- [19] Mokhtari S, Houshi S, Mirmosayyeb O, Barzegar M, Afshari-Safavi A and Ghasemi M, et al. (2023) Demographic and clinical characteristics of familial and sporadic multiple sclerosis patients. *International Journal of Preventive Medicine*. 2023 Jun 1;14(1):86.
- [20] Manjunatha RT, Habib S, Sangaraju SL, Yopez D, Grandes XA and Grandes X. (2022). Multiple sclerosis: therapeutic strategies on the horizon. *Cureus*. 2022 May 10;14(5).
- [21] Ömerhoca S, Akkaş SY and İçen NK. (2018). Multiple Sclerosis: Diagnosis and Differential Diagnosis. *Noro Psikiyatı Ars*. 2018;55(Suppl 1):S1-S9.
- [22] Piehl F. (2021). Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis. *J Intern Med*. 2021 Jun;289(6):771-791.
- [23] Ponzio M, Tacchino A, Amicizia D, Piazza MF, Paganino C and Trucchi C, et al. (2022). Prevalence of multiple sclerosis in Liguria region, Italy: an estimate using the capture–recapture method. *Neurological Sciences*. 2022 May;43(5):3239-45.
- [24] Rojas JI, Patrucco L, Miguez J, Sinay V, Cassara FP and Cáceres F (2016). Disease onset in familial and sporadic multiple sclerosis in Argentina. *Multiple Sclerosis and Related Disorders*. 2016 Mar 1;6:54-6.
- [25] Sun Y, Yu H and Guan Y. (2023) Glia connect inflammation and neurodegeneration in multiple sclerosis. *Neuroscience Bulletin*. 2023 Mar;39(3):466-78.
- [26] Schmidt S and Jöstingmeyer P. (2019). Depression, fatigue and disability are independently associated with quality of life in patients with multiple sclerosis: results of a cross-sectional study. *Multiple sclerosis and related disorders*. 2019 Oct 1;35:262-9.
- [27] Steenhof M, Stenager E, Nielsen NM, Kyvik K, Möller S and Hertz JM. (2019). Familial multiple sclerosis patients have a shorter delay in diagnosis than sporadic cases. *Multiple sclerosis and related disorders*. 2019 Jul 1;32:97-102.
- [28] Walton C, King R, Rechtman L, Kaye W, Leray E and Marrie RA (2020) Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS. *Multiple Sclerosis Journal*. 2020 Dec;26(14):1816-21.
- [29] Younger DS. (2022). Multiple sclerosis: Motor dysfunction. In *Handbook of Clinical Neurology* 2023 Jan 1 (Vol. 196, pp. 119-147). Elsevier.
- [30] Zivadinov R, Bergsland N and Dwyer MG. (2018). Atrophied brain lesion volume, a magnetic resonance imaging biomarker for monitoring neurodegenerative changes in multiple sclerosis. *Quantitative Imaging in Medicine and Surgery*. 2018 Nov;8(10):979.